Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
Introduction: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, metabolic associated fatty liver disease, and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to...
| Publicado en: | Annals of Nutrition & Metabolism Vol. 79; no. 6; pp. 522 - 528 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Karger AG
2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174869727&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 174869727 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02506807 8BM jtl: Annals of Nutrition & Metabolism issn: 02506807 maglogo: N pubinfo: dt: 2023 vid: 79 iid: 6 pid: 2485 pub: Karger AG artinfo: ui: 174869727 173883255 174869727 174869727 10.1159/000534725 174869727 ppf: 522 ppct: 6 formats: tig: atl: Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial. aug: au: Stenlid, Rasmus Cerenius, Sara Y. Manell, Hannes Küçükemre Aydin, Banu Mörwald, Katharina Gomahr, Julian Höghammar Mitkas, Marina Eriksson, Ida Ciba, Iris Geiersberger, Sabine Thivel, David Weghuber, Daniel Bergsten, Peter Forslund, Anders affil: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden sug: subj: Pediatric Obesity Drug Therapy Inflammation In Adolescence Exenatide Therapeutic Use Exenatide Pharmacodynamics Antiinflammatory Agents Biological Markers Blood Human Female Male Adolescence Randomized Controlled Trials Random Assignment Multicenter Studies Double-Blind Studies Control Group Injections, Subcutaneous Exenatide Administration and Dosage Placebos Sample Size Determination Treatment Duration Receptors, Cell Surface Drug Effects Outcome Assessment Vascular Endothelial Growth Factors Drug Effects T-Tests Data Analysis Software Descriptive Statistics Funding Source Adolescent: 13-18 years Female Male ab: Introduction: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, metabolic associated fatty liver disease, and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated. Methods: Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 92 inflammatory proteins were measured. Results: Following treatment with exenatide, 15 out of the 92 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL-18Rα was significantly lowered following treatment. Conclusions: Weekly injections with 2 mg of exenatide lowers circulating IL-18Rα in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|